Medical Device Company R3 Vascular Inc. Appoints New Vice President of Global Clinical and Scientific Affairs
On July 11, 2024, R3 Vascular Inc., a medical device company headquartered in Mountain View, CA, announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. The company specializes in developing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD).
Josh Smale’s Background and Experience
Before joining R3 Vascular, Smale worked for Becton Dickinson (BD) as Vice President of Clinical Affairs for the Peripheral Intervention business unit where he was responsible for all aspects of clinical evidence generation and dissemination for the company’s diverse device portfolio. Smale has also served in roles of increasing responsibility for Bard Peripheral Vascular, Inc. (BPV) and as Regulatory Affairs Manager for SenoRX, Inc. Additionally, he served as Regulatory Affairs Manager for Endologix, Inc.
Smale has more than 20 years of relevant medical device experience specialized in clinical and regulatory affairs strategy, clinical evidence generation and dissemination, and physician education. He has received numerous awards, is the co-author of several publications, and holds five Vena Cava Filter patents.
R3 Vascular’s Technology Platform
R3 Vascular is a privately-held medical device company that develops a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds. The company’s scaffolds deliver the support of a scaffold along with the anti-inflammatory and anti-proliferative result of sirolimus and then ‘disappear’ over time as the vessel heals.
Clinical Trial Efforts and Future Developments
Smale will lead R3 Vascular’s clinical trial efforts, including the pivotal ELITE trial for the company’s next generation Magnitude drug eluting bioresorbable scaffold. This major clinical trial will help demonstrate the efficacy of R3 Vascular’s innovative new technology for treating peripheral arterial disease.
With Smale’s extensive experience and expertise in clinical and regulatory affairs, R3 Vascular is well-positioned to make breakthroughs in the treatment of peripheral arterial disease. Their innovative bioresorbable scaffolds have revolutionized the field, offering a more effective and minimally invasive treatment option while minimizing long term side effects.
Long-tail Keywords:
R3 Vascular, bioresorbable scaffolds, Peripheral arterial disease, drug eluting, sirolimus, Magnitude, clinical trial, regulatory affairs, physician education, medical device, Becton Dickinson, Bard Peripheral Vascular, SenoRX, Endologix.
Originally Post From https://www.dicardiology.com/content/r3-vascular-appoints-josh-smale-vice-president-global-clinical-and-scientific-affairs
